Gemcitabine

Catalog No.S1714

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Price Stock Quantity  
USD 130 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7iTWM2OD1yLkCwNFQ2QCCwTR?=M3jYd3NCVkeHUh?=
ES4MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzNVHpKSzVyPUCuNFAxPjV|IH7NM1TlV3NCVkeHUh?=
ACHNM2XBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwMECwPFg4KG6PM4fkXHNCVkeHUh?=
KYSE-510NGfMeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwMECwPVc2KG6PNUPIOXBFW0GQR1XS
EW-7M{LRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmKxTWM2OD1yLkCwNlU5KG6PNX30OVdsW0GQR1XS
BFTC-905NH;OV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTBwMEC1NVUhdk1?M{nHRnNCVkeHUh?=
KE-37MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTBwMEC1OlEhdk1?MVHTRW5ITVJ?
SBC-5NEK2TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjtRmhKSzVyPUCuNFA2PyCwTR?=MkjVV2FPT0WU
NKM-1MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDrUFlKSzVyPUCuNFA4ODlibl2=M4Po[nNCVkeHUh?=
RH-1NY[2do92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3EUZRKSzVyPUCuNFA4OThibl2=M{n3[HNCVkeHUh?=
ALL-PONYTPV5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHzNWd5UUN3ME2wMlAxQDNibl2=MknIV2FPT0WU
QIMR-WILNU\BeoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTp[mJKSzVyPUCuNFA5QTRibl2=M{f6b3NCVkeHUh?=
A375MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTBwMEC5PVUhdk1?NYLUNnBJW0GQR1XS
SIG-M5M4\zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGX6U3JKSzVyPUCuNFExPCCwTR?=NHjzWndUSU6JRWK=
KGNMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rBVmlEPTB;MD6wNVA5KG6PNGOyS4FUSU6JRWK=
EW-13MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PBSmlEPTB;MD6wNVEzKG6PMk\wV2FPT0WU
NCI-SNU-1M2P2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XlW2lEPTB;MD6wNVYhdk1?M{Xjc3NCVkeHUh?=
PSN1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjsTWM2OD1yLkCxOlUhdk1?MU\TRW5ITVJ?
HUTU-80NEG3dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwMEG2OkBvVQ>?MVfTRW5ITVJ?
EW-16MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLFfJBKSzVyPUCuNFI{KG6PM2K3[XNCVkeHUh?=
786-0NUm2[I1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXn1eFVlUUN3ME2wMlAzOyCwTR?=MnPWV2FPT0WU
ES1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jQOWlEPTB;MD6wNlY5KG6PMULTRW5ITVJ?
RKONU\h[FlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTBwMEK3PUBvVQ>?NGHjT3FUSU6JRWK=
ESS-1NXPRV5FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3OxTmlEPTB;MD6wNlg3KG6PMYfTRW5ITVJ?
SK-UT-1NIGyZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGxTWM2OD1yLkCyPVchdk1?Ml7QV2FPT0WU
LB2241-RCCNEnRS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPBTWM2OD1yLkCzNVghdk1?MVzTRW5ITVJ?
CHL-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjF[FVlUUN3ME2wMlA{OjRibl2=NIfUdnZUSU6JRWK=
SW1783M3\teGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTBwMEOzOkBvVQ>?Ml\nV2FPT0WU
MEL-JUSOMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvrXopKUUN3ME2wMlA{QTFibl2=Moj6V2FPT0WU
HT-29Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvsRZJ2UUN3ME2wMlA1OTNibl2=M37hfXNCVkeHUh?=
SNG-MMofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\xdZZQUUN3ME2wMlA1OjVibl2=MV3TRW5ITVJ?
TE-15NHjUfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PieGlEPTB;MD6wOFY1KG6PMYjTRW5ITVJ?
HOSMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXL5WGk2UUN3ME2wMlA1QCCwTR?=Ml3aV2FPT0WU
BB65-RCCNHnKcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomxTWM2OD1yLkC1NVIhdk1?NVXVTHdrW0GQR1XS
HCE-4M2\2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rlVmlEPTB;MD6wOVI5KG6PMmL0V2FPT0WU
MHH-ES-1M1XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\JTWM2OD1yLkC1N|Ehdk1?NWPINldFW0GQR1XS
RPMI-7951MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\X[YRKSzVyPUCuNFU1OSCwTR?=NFfBWpRUSU6JRWK=
IST-SL2NFzaRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fHVGlEPTB;MD6wOVg1KG6PMn7XV2FPT0WU
CMKNIjn[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInFR4lKSzVyPUCuNFU5PiCwTR?=NFPGWJhUSU6JRWK=
GR-STM1nEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVOwd5hGUUN3ME2wMlA2QTVibl2=NF\2V41USU6JRWK=
NALM-6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTBwME[yNkBvVQ>?NV;KXlJ[W0GQR1XS
RPMI-6666NFrMT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkf3TWM2OD1yLkC2OVIhdk1?Ml;BV2FPT0WU
LC-2-adM2jkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTSNIV{UUN3ME2wMlA3PTNibl2=NWrMfoMxW0GQR1XS
ARH-77NIDX[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlL4TWM2OD1yLkC3NVEhdk1?M1PsWHNCVkeHUh?=
IST-MEL1M{LMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPLTWM2OD1yLkC3NlYhdk1?NYLXO203W0GQR1XS
SW1710Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DOUGlEPTB;MD6wO|UyKG6PM2jhZ3NCVkeHUh?=
DELMlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTBwMEi4O{BvVQ>?M4fhXnNCVkeHUh?=
AGSNXP1SGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwMEmwNkBvVQ>?NYSxN5l{W0GQR1XS
NCI-H2122M174S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vBXGlEPTB;MD6wPVQ3KG6PMk\GV2FPT0WU
HSC-4MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PnVGlEPTB;MD6xNFIhdk1?NYrGU|VxW0GQR1XS
AM-38MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwMUKxJI5OMWnTRW5ITVJ?
769-PNIjPXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTBwMUKzJI5ONF3wZZBUSU6JRWK=
RT-112Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW5bodQUUN3ME2wMlEzPyCwTR?=MWDTRW5ITVJ?
MCF7NVPVUYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHMTWM2OD1yLkGzOkBvVQ>?M3XYRXNCVkeHUh?=
IGROV-1MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HCcmlEPTB;MD6xOFUhdk1?MWfTRW5ITVJ?
OCI-AML2MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMUS3JI5ONWLZUZNkW0GQR1XS
NCI-H1299MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPMb5A5UUN3ME2wMlE2PyCwTR?=NW\6[WtSW0GQR1XS
A431Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwMUizJI5OM{noPXNCVkeHUh?=
SW982NIr1OGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LQO2lEPTB;MD6yNVMhdk1?NEiyRXVUSU6JRWK=
BB30-HNCMnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlWwTWM2OD1yLkKzNUBvVQ>?MV7TRW5ITVJ?
ACNMn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkO1TWM2OD1yLkK0OEBvVQ>?MVnTRW5ITVJ?
647-VM4nKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTBwMkS4JI5OMVHTRW5ITVJ?
SK-PN-DWMoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLsTWM2OD1yLkK2OkBvVQ>?NE\QeIxUSU6JRWK=
LCLC-97TM1M1nMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHYUXJKSzVyPUCuNlY4KG6PNX3OO41yW0GQR1XS
LB1047-RCCM{nVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;xeFJKSzVyPUCuNlY6KG6PMmTNV2FPT0WU
A2780MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfZTWM2OD1yLkK3JI5ONF[2e29USU6JRWK=
C-33-ANUixRlM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXH6dYZNUUN3ME2wMlI4OyCwTR?=NFn2NJFUSU6JRWK=
NCI-H2228M4H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDhfXdKSzVyPUCuN|E1KG6PMmrZV2FPT0WU
TE-5NFvVTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjvVmZKSzVyPUCuN|E3KG6PNU[4bXM5W0GQR1XS
HC-1NHXtS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPFTWM2OD1yLkOyO{BvVQ>?M2W4bXNCVkeHUh?=
SK-MES-1NWfSZm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\HPZZzUUN3ME2wMlMzQCCwTR?=NVfj[opWW0GQR1XS
NCI-H1355NUPLTm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV2wZ3ZPUUN3ME2wMlM5OSCwTR?=NUPsSHBIW0GQR1XS
YKG-1NUfDdFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjzfVd{UUN3ME2wMlQyQSCwTR?=MmDJV2FPT0WU
RS4-11M3zjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LQTWlEPTB;MD60N|Mhdk1?MnmzV2FPT0WU
DaoyM3\0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPtZZpbUUN3ME2wMlQ2PiCwTR?=MUPTRW5ITVJ?
A3-KAWNUXw[oVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrue3JCUUN3ME2wMlU2OSCwTR?=MVXTRW5ITVJ?
SK-MEL-30NEDwXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTxTWM2OD1yLkW1OEBvVQ>?NXyxe|VDW0GQR1XS
U031Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPSbY1yUUN3ME2wMlU3PSCwTR?=NUjSeZhkW0GQR1XS
SK-LMS-1NEX6SYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHPdlk5UUN3ME2wMlU4QCCwTR?=M37GS3NCVkeHUh?=
ES6M1qyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXpfolKSzVyPUCuOVg3KG6PNIqyOZZUSU6JRWK=
EoL-1-cellM1fxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PUPGlEPTB;MD62NVYhdk1?MVvTRW5ITVJ?
NCI-H2009M1fIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O1dGlEPTB;MD62NVkhdk1?MmHOV2FPT0WU
A4-FukM3nmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\5[WlEPTB;MD62NlYhdk1?MVjTRW5ITVJ?
KYSE-270NFSxc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DPb2lEPTB;MD62N|Qhdk1?MXTTRW5ITVJ?
SK-LU-1Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfCVJlRUUN3ME2wMlY2PSCwTR?=M{jnW3NCVkeHUh?=
SW872NWrrXllvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILIbmRKSzVyPUCuO|Y2KG6PMmX6V2FPT0WU
ES8NHLyNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3yzbmlEPTB;MD63PEBvVQ>?Mln0V2FPT0WU
G-402M4XGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\QW2ZWUUN3ME2wMlc5PCCwTR?=NH7NUJVUSU6JRWK=
ATN-1Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\LcIFkUUN3ME2wMlgxPyCwTR?=MnzSV2FPT0WU
DoTc2-4510MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwOUCxJI5ONH;pZ2NUSU6JRWK=
MES-SAM3fIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml:5TWM2OD1yLkmwOUBvVQ>?NXPqd5M6W0GQR1XS
SF268NWnvVW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwOUK3JI5ONUHkT4tPW0GQR1XS
SF539NYPhSY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlK0TWM2OD1zLkCyJI5ONGDOV2hUSU6JRWK=
NB69NFnSfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nWSGlEPTB;MT6wOUBvVQ>?MnruV2FPT0WU
8505CNYfvSXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\Y[2lEPTB;MT6wOkBvVQ>?M1;1[3NCVkeHUh?=
CAL-12TNXnldmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi3eYlKSzVyPUGuNFghdk1?MorTV2FPT0WU
BHYNFLEUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TwRmlEPTB;MT6xOEBvVQ>?NXHlcmYxW0GQR1XS
LB647-SCLCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTFwMUigcm0>MmTYV2FPT0WU
CAL-62MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVu0e2RLUUN3ME2xMlIzKG6PMUDTRW5ITVJ?
MEG-01Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXWTWM2OD1zLkK3JI5ONGS3cFdUSU6JRWK=
MG-63MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwM{Ogcm0>M{LIRnNCVkeHUh?=
SW620NYLZRmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXzNnVKSzVyPUGuN|Uhdk1?MnTGV2FPT0WU
A388NVrTfmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{mzfmlEPTB;MT6zOkBvVQ>?NXftVHZ4W0GQR1XS
BCPAPNEDVSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3I[IxXUUN3ME2xMlQ2KG6PMn\EV2FPT0WU
P30-OHKNXHHcHRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4KzVmlEPTB;MT60OkBvVQ>?MkHZV2FPT0WU
Ca9-22M4fQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmezTWM2OD1zLkW0JI5OM3nJXHNCVkeHUh?=
VMRC-RCZNGXCfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\ES2lqUUN3ME2xMlU1KG6PMlzsV2FPT0WU
LOXIMVIMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfJTWM2OD1zLk[gcm0>NF\jZmdUSU6JRWK=
L-540M33Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTFwNjDuUS=>MUDTRW5ITVJ?
NTERA-S-cl-D1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LRd2lEPTB;MT62OEBvVQ>?M3LZ[HNCVkeHUh?=
MFH-inoMlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;YVohOUUN3ME2xMlY3KG6PM1LwenNCVkeHUh?=
Calu-6MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXG2UHJyUUN3ME2xMlc{KG6PMn3SV2FPT0WU
HELMknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTFwN{mgcm0>MkfHV2FPT0WU
CAL-33NUDPcZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXqydYtTUUN3ME2xMlg6KG6PMnLDV2FPT0WU
HSC-3MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHTPVhKSzVyPUGuPVEhdk1?MWHTRW5ITVJ?
KU812M1y1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnmzTWM2OD1zLkmxJI5OMnSzV2FPT0WU
EB2M{nTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXwTWM2OD1{LkCxJI5OMYnTRW5ITVJ?
SRM1;Fc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH6ySlVKSzVyPUKuNVIhdk1?NEL1TGhUSU6JRWK=
NCI-H2087M1XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkflTWM2OD1{LkG0JI5OM1LvZ3NCVkeHUh?=
H4MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTJwMUigcm0>NIHDXI1USU6JRWK=
EW-1NWfLSJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fkWGlEPTB;Mj6yNkBvVQ>?MWXTRW5ITVJ?
MC-IXCMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPZR49KSzVyPUKuNlYhdk1?NYHENoRWW0GQR1XS
NCI-H727MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2OzfmlEPTB;Mj61NUBvVQ>?MXPTRW5ITVJ?
MRK-nu-1NFHyOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XVS2lEPTB;Mj61O{BvVQ>?NGT0SodUSU6JRWK=
COLO-668NYTRfYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYToRYNSUUN3ME2yMlY3KG6PM3zqT3NCVkeHUh?=
CGTH-W-1NWrVfW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTJwN{Kgcm0>MmjtV2FPT0WU
CHP-212NWPmN2ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTJwN{Wgcm0>NEDCcFVUSU6JRWK=
GI-1M1zPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3n3eGlEPTB;Mj63OkBvVQ>?NH;B[GFUSU6JRWK=
HCC1806NGKz[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDXT3N3UUN3ME2yMlkyKG6PNHnlbWdUSU6JRWK=
HLEM4\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrsXGtKSzVyPUOgcm0>MXjTRW5ITVJ?
HSC-2M4PPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHVZWFKSzVyPUOuNFMhdk1?NImyeY9USU6JRWK=
DMS-273NYr1ZVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ryUGlEPTB;Mz6wO{BvVQ>?NWjqXXNXW0GQR1XS
DU-4475MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjIOVhKSzVyPUOuNVQhdk1?NWLRWWhTW0GQR1XS
LXF-289MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPNfG5KSzVyPUOuN|Ehdk1?M2Tze3NCVkeHUh?=
PANC-03-27MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXvVY5KSzVyPUOuOVEhdk1?NVHBc4h3W0GQR1XS
GAMGNWHEdFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nnVGlEPTB;Mz63OEBvVQ>?NWTo[3lCW0GQR1XS
NCI-H522MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\HTWM2OD12LkO0JI5OMmfxV2FPT0WU
SW626NFTxeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTRwNE[gcm0>NUjkcFVSW0GQR1XS
HT-144MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlniTWM2OD12LkmyJI5ONF[wfINUSU6JRWK=
MEL-HONWTV[pZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3j2cWlEPTB;NT6xOkBvVQ>?MXPTRW5ITVJ?
BE-13MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXNRol4UUN3ME21MlIyKG6PNWnu[XhQW0GQR1XS
VA-ES-BJNIPTcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[xTWM2OD13LkK2JI5OMnLnV2FPT0WU
NCI-H441NUO0WmRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HnbGlEPTB;NT62JI5OM3jWbXNCVkeHUh?=
KP-4NWTFPFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3KyfWlEPTB;NT62NUBvVQ>?NGH3XG9USU6JRWK=
LoVoNYqzPYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTVwN{Ggcm0>NFjST2lUSU6JRWK=
HT-1080MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXLTWM2OD13LkizJI5OMWnTRW5ITVJ?
GB-1MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlH6TWM2OD13Lki0JI5ONGrnepVUSU6JRWK=
IA-LMNV3wXHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nZfGlEPTB;NT65NUBvVQ>?MVvTRW5ITVJ?
8-MG-BANHjINXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTibnFKSzVyPUWuPVMhdk1?NFjYWVdUSU6JRWK=
SK-HEP-1MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;3cmlEPTB;Nj6xOEBvVQ>?NEnBT5VUSU6JRWK=
697MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGC2Uo1KSzVyPU[uNlUhdk1?M2ntNXNCVkeHUh?=
KYSE-450NVPEUYJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTZwM{Kgcm0>MY\TRW5ITVJ?
HCC2998NIe2fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3kTWM2OD14LkO0JI5OMlvuV2FPT0WU
HD-MY-ZMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTZwNkigcm0>MX3TRW5ITVJ?
OS-RC-2NX7B[3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTZwNkigcm0>MmTlV2FPT0WU
SF126MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjFTWM2OD15LkC1JI5ONGHRd3NUSU6JRWK=
Ca-SkiNX;5b2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTdwMEmgcm0>NEfCcpVUSU6JRWK=
NCI-H358M13tOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfoT|ZXUUN3ME23MlE3KG6PM4nrPHNCVkeHUh?=
J82MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3YTWM2OD15LkSxJI5ONYX5cWJHW0GQR1XS
NCI-H2342NXixeZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTdwNkOgcm0>M{LrdHNCVkeHUh?=
OVCAR-8NFL4N49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPEfZBKSzVyPUeuPUBvVQ>?NW[zVYlTW0GQR1XS
TE-8M{DLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHQTWM2OD16IH7NMnHOV2FPT0WU
ETK-1M4fGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXnTWM2OD16LkC4JI5OM4LLZXNCVkeHUh?=
HAL-01MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jGPWlEPTB;OD6yJI5OMom2V2FPT0WU
KYSE-150MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\6UFRWUUN3ME24MlQ4KG6PM2DiSHNCVkeHUh?=
NCI-H810NG\YWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHCTFFKSzVyPUiuOVYhdk1?NETGUllUSU6JRWK=
ONS-76MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjnTWM2OD16Lk[4JI5OMkK3V2FPT0WU
NMC-G1M4i1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT4cVFKSzVyPUiuO|Yhdk1?Mnj0V2FPT0WU
C3AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDWbZBzUUN3ME24Mlg1KG6PM4HXXXNCVkeHUh?=
PA-1M{Pq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPEdG5KSzVyPUiuPVkhdk1?MkfTV2FPT0WU
SH-4Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NESwVVhKSzVyPUmuNFIhdk1?Mmi0V2FPT0WU
EFO-27NEXRbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7vWGJKSzVyPUmuNFUhdk1?NXfBU|h4W0GQR1XS
CAPAN-1NXvzSmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTlwMkOgcm0>M2PI[HNCVkeHUh?=
DU-145NIfOOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUT6S|JRUUN3ME25MlI6KG6PNYrBXZVtW0GQR1XS
A101DM1K1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDXTZlKSzVyPUmuN|chdk1?M{XPOnNCVkeHUh?=
ST486NFrMTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXOW2Q1UUN3ME25MlQyKG6PMm\BV2FPT0WU
NCI-H1437MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTlwNEKgcm0>NIrTfY1USU6JRWK=
HGC-27NFn6bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYC4[IhxUUN3ME25MlYhdk1?MmTwV2FPT0WU
8305CMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;PS2lEPTB;OT62OEBvVQ>?MYXTRW5ITVJ?
OCUB-MM{e0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFyLkCzJI5OMn3JV2FPT0WU
COLO-679MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFyLkC3JI5OMnfQV2FPT0WU
Detroit562M2rmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFyLkSyJI5ONUWxZW5LW0GQR1XS
A204MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPMTWM2OD1zMT6xOkBvVQ>?NXLhPHJmW0GQR1XS
NCI-H1734MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWX5[pFWUUN3ME2xNU4zQSCwTR?=MXfTRW5ITVJ?
MC-CARMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTFzLkW4JI5ONHLacnZUSU6JRWK=
NCI-H2170NX\XdFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTFzLkm3JI5OMnWyV2FPT0WU
NCI-SNU-5M3zxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUSwUGo6UUN3ME2xNk4yOyCwTR?=NYfZeGhIW0GQR1XS
HCE-TNEHMeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLnRphTUUN3ME2xNk41OiCwTR?=NV7XcoNnW0GQR1XS
KYSE-180NGmwN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLnZ41KSzVyPUGyMlgyKG6PNEDNbnZUSU6JRWK=
C8166NHGyUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrFXJNKSzVyPUGzMlA5KG6PMVfTRW5ITVJ?
NCI-H460M{nqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\TS2lEPTB;MUOuOVQhdk1?M{nsSXNCVkeHUh?=
SNU-449NFOyT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vHdmlEPTB;MUOuO|chdk1?NWPrS4tFW0GQR1XS
MDA-MB-468NXjUW|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLpT4ZKSzVyPUG0MlEzKG6PNXfLUIRXW0GQR1XS
COR-L23MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X2OWlEPTB;MUSuNVMhdk1?MVjTRW5ITVJ?
CTV-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDGVWc2UUN3ME2xOE4yPCCwTR?=MV\TRW5ITVJ?
BL-41MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2ThWWlEPTB;MUSuN|chdk1?MnnsV2FPT0WU
IGR-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU[3SpBUUUN3ME2xOE41OiCwTR?=NITwTXBUSU6JRWK=
TK10Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;4SJNKSzVyPUG0MlQ6KG6PMVvTRW5ITVJ?
REHMkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NImwdHJKSzVyPUG0MlUyKG6PMYDTRW5ITVJ?
LU-139MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HrfGlEPTB;MUSuOVkhdk1?M1Hn[nNCVkeHUh?=
KP-N-YSNHnPWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTF2Lkm3JI5OMlLxV2FPT0WU
PANC-10-05NFHUVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHKTWM2OD1zNT6zPEBvVQ>?NV:zOXR3W0GQR1XS
HL-60NHLXZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jicmlEPTB;MUWuOlkhdk1?MkW4V2FPT0WU
T84NXjLd|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTF3Lkm2JI5ONVrOSm81W0GQR1XS
RPMI-8226MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3wVJBKSzVyPUG2MlAzKG6PNI\VS|hUSU6JRWK=
UM-UC-3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLZTGI{UUN3ME2xOk4yPiCwTR?=MXLTRW5ITVJ?
TE-10MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTEV2hlUUN3ME2xOk4zOSCwTR?=M4jDT3NCVkeHUh?=
CAL-148Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTF5LkKzJI5OM{PiRXNCVkeHUh?=
BV-173MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jpcGlEPTB;MUeuNlchdk1?M2rHZXNCVkeHUh?=
Calu-3M3LlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTF5LkK5JI5OMl75V2FPT0WU
RPMI-2650NYPFSmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD2TWM2OD1zNz61PUBvVQ>?M1TSb3NCVkeHUh?=
MKN45NHXD[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrYfVdFUUN3ME2xO{44OyCwTR?=NYfjOJp7W0GQR1XS
NUGC-3NYHaeZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrCO2JKSzVyPUG4MlM1KG6PNWDPPJdSW0GQR1XS
NCI-H520MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF6Lke3JI5OM1ziZXNCVkeHUh?=
CCRF-CEMNH\WcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF6Lki1JI5ONITweZVUSU6JRWK=
NCI-H2405NF\sZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF7LkGgcm0>M1O0b3NCVkeHUh?=
ES7MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUX1SmtCUUN3ME2xPU44PiCwTR?=NVHZVWlwW0GQR1XS
BPH-1Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4i4UGlEPTB;MkCuNlghdk1?M4rwPXNCVkeHUh?=
SASMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLoTWM2OD1{MD61JI5ONFrRdpdUSU6JRWK=
HuCCT1NXTGe2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\q[3pSUUN3ME2yNE42QCCwTR?=NUXNXYRkW0GQR1XS
LOUCYMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIf4[mVKSzVyPUKwMlY3KG6PM3PtUXNCVkeHUh?=
NCI-H292NGXOfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHLTWM2OD1{MD63PUBvVQ>?MVjTRW5ITVJ?
G-361M1HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvkZnNKSzVyPUKxMlA4KG6PMkGzV2FPT0WU
M059JNGTSfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTJzLkC4JI5OMl6yV2FPT0WU
NCI-H1651NVjSeoc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rq[mlEPTB;MkGuNVEhdk1?MmrFV2FPT0WU
KALS-1NHz6SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJzLkO5JI5ONFXnSJdUSU6JRWK=
DJM-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYThPXA3UUN3ME2yNU42QSCwTR?=NWHZSmVvW0GQR1XS
AU565MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XsR2lEPTB;MkGuPFMhdk1?NEjmTXhUSU6JRWK=
HCC38NY\kXZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml74TWM2OD1{MT65OUBvVQ>?M1fYbHNCVkeHUh?=
U251NUPqT5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHzTWM2OD1{Mj6yO{BvVQ>?NIXKR|NUSU6JRWK=
ABC-1NIW0WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4T0VWlEPTB;MkKuOlUhdk1?MknaV2FPT0WU
SK-NEP-1NE\JNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfv[Y9KSzVyPUKyMlk{KG6PNVXSSYZUW0GQR1XS
CESSM4[3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2f0UmlEPTB;MkOuNVkhdk1?M1L5THNCVkeHUh?=
MIA-PaCa-2Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfRe5dKSzVyPUKzMlM3KG6PM4XI[XNCVkeHUh?=
SUP-T1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIT5[FJKSzVyPUKzMlQ4KG6PM1vHUXNCVkeHUh?=
L-428NGPhW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jmTWlEPTB;MkOuOlIhdk1?M13rUXNCVkeHUh?=
SW954MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3SfG1KSzVyPUKzMlY5KG6PMmjjV2FPT0WU
HO-1-N-1NWrZRZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmO2TWM2OD1{Mz63O{BvVQ>?MVTTRW5ITVJ?
CHP-126NV\kV2t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrTbphKSzVyPUK0MlE1KG6PMWrTRW5ITVJ?
HMV-IIMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTI[W56UUN3ME2yOE4{PCCwTR?=NFz5do9USU6JRWK=
NB10MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3YPVZlUUN3ME2yOE4{PyCwTR?=MVnTRW5ITVJ?
A172M2L0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHW3TZRKSzVyPUK0MlcyKG6PM1;pRXNCVkeHUh?=
MONO-MAC-6NH;4THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu1WmpKSzVyPUK0Mlg1KG6PNUfEVGVsW0GQR1XS
NCI-H1650NFnDOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPZS4xKSzVyPUK1MlQhdk1?MVTTRW5ITVJ?
NH-12NXHuR5ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTJ3LkWgcm0>MkizV2FPT0WU
ML-2NGPENZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fpW2lEPTB;MkWuO|Qhdk1?NFzKcZVUSU6JRWK=
MZ2-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33ieGlEPTB;Mk[uNlIhdk1?M4TSRnNCVkeHUh?=
COLO-684M1\X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LKSGlEPTB;Mk[uOFEhdk1?MnzlV2FPT0WU
HuP-T4NITMV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETPc2VKSzVyPUK3MlMhdk1?M1[2cnNCVkeHUh?=
SW837M1vt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{KzUmlEPTB;MkeuOlIhdk1?NEXWU2JUSU6JRWK=
MDA-MB-231NGXuWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;0emlEPTB;MkeuO|ghdk1?NF7tZ4VUSU6JRWK=
KYSE-140MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NViw[ll5UUN3ME2yO{46OSCwTR?=MXLTRW5ITVJ?
NOMO-1MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofhTWM2OD1{OD62PEBvVQ>?Mn7JV2FPT0WU
GP5dNVr0W49ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7xUlhKSzVyPUK4MlczKG6PMlzqV2FPT0WU
COR-L105M4e5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUWwellNUUN3ME2yPU41OiCwTR?=NVHWT4Z2W0GQR1XS
LS-411NMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJ7Lki4JI5OMoXkV2FPT0WU
NYNI[1WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jtdGlEPTB;M{CuNVghdk1?M4XEWHNCVkeHUh?=
NCI-H2030M1;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXsTWM2OD1|MD60OUBvVQ>?MXfTRW5ITVJ?
CCF-STTG1MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;jUpZKSzVyPUOxMlQzKG6PMofoV2FPT0WU
NCI-H1703NIiybGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NES3T45KSzVyPUOxMlc5KG6PMXjTRW5ITVJ?
TURMmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTN{LkCzJI5OMVHTRW5ITVJ?
NOS-1Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPzfGJKSzVyPUOyMlQ1KG6PNH;rWGJUSU6JRWK=
A2058M1PLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzRSJBLUUN3ME2zNk45OyCwTR?=MXPTRW5ITVJ?
LCLC-103HMkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnvTWM2OD1|Mz6yOUBvVQ>?M3LqV3NCVkeHUh?=
NCI-H510AMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX6WXBbUUN3ME2zN{4zPyCwTR?=NXnk[HRbW0GQR1XS
BC-1M173PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILu[|dKSzVyPUOzMlc4KG6PNEXHcnRUSU6JRWK=
SK-CO-1MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV2z[XZqUUN3ME2zOE4xOSCwTR?=MX3TRW5ITVJ?
A673NXy0fJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFqzVphKSzVyPUO0MlE4KG6PMYfTRW5ITVJ?
VM-CUB-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnK3TWM2OD1|ND62PUBvVQ>?NVGzNGw5W0GQR1XS
HHNEnOem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jwc2lEPTB;M{WuNFYhdk1?NXHQUJlZW0GQR1XS
CAL-27M3PjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrJZohKSzVyPUO1MlE3KG6PMmPhV2FPT0WU
NEC8NUfPXGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PWdGlEPTB;M{WuN|chdk1?NHjzXHdUSU6JRWK=
BxPC-3MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPTTWM2OD1|Nj65NUBvVQ>?NUC4ZVM5W0GQR1XS
SNB75NF3PRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTN5LkK0JI5ONUTWUHRNW0GQR1XS
NB13NW\RWo1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHy4TpJKSzVyPUO4MlI{KG6PNH;3ZoFUSU6JRWK=
SK-OV-3NUDBcHpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTN6Lke0JI5ONI\WcGxUSU6JRWK=
ME-180MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jVRWlEPTB;M{iuPEBvVQ>?NHzhbZFUSU6JRWK=
JiyoyeP-2003MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTN7LkO4JI5ONVzFfllOW0GQR1XS
LU-134-AMn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3my[WlEPTB;NECuNFIhdk1?NUjJVZhOW0GQR1XS
LS-123MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TGUmlEPTB;NECuNlghdk1?MomxV2FPT0WU
COLO-800MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTRyLkW2JI5OMVrTRW5ITVJ?
LB831-BLCNGHBVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;odXdKSzVyPUSxMlg2KG6PMY\TRW5ITVJ?
NCI-H747NYrpO2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\qV2lEPTB;NEKuNlghdk1?NGrjZ2lUSU6JRWK=
MZ7-melM1S5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rtZ2lEPTB;NEKuOlYhdk1?MmLuV2FPT0WU
GT3TKBM1nJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2qxfGlEPTB;NEKuO|Ihdk1?M1vTW3NCVkeHUh?=
MOLT-16NWfnbVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfCZ4tKSzVyPUSzMlA2KG6PNVPtXIpoW0GQR1XS
23132-87M4S2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTR|LkC1JI5OMXnTRW5ITVJ?
PF-382MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXSTWM2OD12ND6yNkBvVQ>?NWrYVWNKW0GQR1XS
ES3NHTrVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\3dFVKSzVyPUS0MlYhdk1?M3H5W3NCVkeHUh?=
SW756NVXMbJNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH36cJFKSzVyPUS1MlE1KG6PMVrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02538432 Not yet recruiting Prostate Cancer|Non-Small Cell Lung Cancer|Breast Cancer University of Maryland January 2017 Phase 2
NCT02806687 Not yet recruiting Pancreatic Adenocarcinoma University Hospital, Toulouse|BIOTHERAPY department of th  ...more University Hospital, Toulouse|BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse|InvivoGen Therapeutics October 2016 Phase 2
NCT02767557 Not yet recruiting Unresectable Pancreatic Carcinoma Herlev Hospital|Celgene|Roche Pharma AG October 2016 Phase 2
NCT02631590 Not yet recruiting Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor H. Lee Moffitt Cancer Center and Research Institute|Bayer September 2016 Phase 2
NCT02741388 Not yet recruiting B-cell Lymphoma The Lymphoma Academic Research Organisation|Karyopharm Th  ...more The Lymphoma Academic Research Organisation|Karyopharm Therapeutics, Inc September 2016 Phase 1

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water 16 mg/mL warming (60.79 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo water 16mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Customer Product Validation(3)


Click to enlarge
Rating
Source Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck
Method Xenograft Study
Cell Lines Athymic nude mice
Concentrations 120 mg/kg
Incubation Time 14 d
Results Gemcitabine treatment caused a threefold increase in stemness-high cell population.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck
Method Immunofluorescence
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 72 h
Results To finally investigate whether incorporation of drugs into RNA could be a general mechanism inducing SG assembly, we tested other chemotherapeutics known to incorporate into RNA, such as 5-azacytidine and 6-thioguanine, or as control, chemotherapeutics known to incorporate mainly into DNA, such as trifluorothymidine (TFT) or gemcitabine. HeLa cells treated with 5-azacytidine and 6-thioguanine displayed TIAR-positive foci, whereas HeLa cells treated with TFT or gemcitabine did exhibit such foci even with higher concentrations applied.

Click to enlarge
Rating
Source Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck
Method MTT assays
Cell Lines MCF7 cells, MCF10A cells
Concentrations 0.01-100 μM
Incubation Time 48 h
Results Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us